Platinum Chemotherapy In Childhood Adds About 2,200 Liver Mutations Per Sample, Study Finds

Platinum-based chemotherapy helped transform outcomes for children with hepatoblastoma, but a new study suggests that benefit can come with durable genetic damage in healthy liver tissue. In research published Thursday in Science, investigators reported that children exposed to platinum agents accumulated hundreds of mutations in genes, averaging 2,200 mutations per liver sample, a burden they said is usually found in adult livers.

The finding does not mean those liver cells will definitely become cancerous. But it does give a more concrete picture of the long-term biological cost of cisplatin and carboplatin in children treated for liver cancer, and it supports closer survivorship follow-up well beyond childhood.

The Data

The study examined children with hepatoblastoma who had received platinum therapy followed by surgery to remove the tumor. Researchers sampled healthy and cancerous liver tissue, along with blood, and analyzed the material using a DNA sequencing method called NanoSeq.

They compared those results with samples from children treated with different drugs or not treated before surgery, as well as fetal liver tissue. The result was a clear mutational signal associated with platinum exposure.

According to the study, the more platinum exposure a child had, the higher the mutation load. Children who received only cisplatin had fewer mutations than those who received both cisplatin and carboplatin. Researchers also found that liver cells carried many more mutations than blood cells even though chemotherapy is systemic.

Foad Rouhani, a paper author and professor at King’s College in London, said the work found cancer genes as well as genes associated with long-term changes in liver metabolism. He added that the evidence points to the potential for these cells to cause problems further down the line, but not certainty that they will do so.

Why The Liver Finding Matters

The central scientific point is not simply that platinum drugs damage DNA, which is already understood, but that in these children the resulting liver mutation burden resembled that of adult tissue. The study describes this as platinum aging the liver cells.

Researchers do not yet know why liver cells appeared more affected than blood cells. Rouhani said platinum may be metabolized differently in the liver, or liver cells may repair the damage differently. He also said the causality could be read the other way around: the extent of mutations may help explain why that liver became sick in the first place.

That uncertainty matters. The paper does not present a settled mechanism, but it does establish that the damage occurs. For clinicians, that is enough to strengthen the case for longer-term surveillance of survivors for liver pathologies or secondary tumors.

In a perspective article, Sanjeev Vasudevan and Donald Williams Parsons, both professors at Baylor College of Medicine in Houston, wrote that the findings provide strong evidence for survivorship studies of children treated for liver cancer beyond their third decade of life.

For drug development, the longer-range implication is more specific than a general warning about chemotherapy toxicity. Rouhani said understanding the mechanism could eventually help researchers design next-generation chemotherapies that remain effective against cancer while leaving background tissue largely untouched. That makes this study less a challenge to current platinum use than a signal about where future oncology innovation may need to improve.